Quay Pharma
Quay Pharma is a privately held pharmaceutical contract development, manufacturing, and packaging organisation (CDMO), founded in 2002 and based in Deeside, operating with 101-250 employees under CEO Maireadh Pedersen and Chairman Mike Rubinstein.
- Company typePrivate
- Founded2002
- HeadquartersDeeside, Australia
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Quay Pharma firmographics
Firmographics- Name
- Quay Pharma
- Website
- https://quaypharma.com
- Company type
- Private
- Founded year
- 2002
- Headcount range
- 101–250 employees
- Short description
- Quay Pharma is a privately held pharmaceutical contract development, manufacturing, and packaging organisation (CDMO), founded in 2002 and based in Deeside, operating with 101-250 employees under CEO Maireadh Pedersen and Chairman Mike Rubinstein.
- Ownership category
- akta.pro rank
Quay Pharma industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Small-Molecule API & Intermediates CDMO (HLAGABAA)
Keywords
Where Quay Pharma is headquartered
LocationHeadquarters
- HQ city
- Deeside
- HQ country
- Australia
- HQ region
- Oceania
Markets served
Quay Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D
Quay Pharma product offering
Product offeringCore offering
Quay Pharma is a contract development, manufacturing and packaging organisation serving the pharmaceutical industry. It delivers outsourced services across drug development, manufacturing, and packaging to pharmaceutical clients worldwide. The company operates as a private for-profit CDMO with 101–250 employees, founded in 2002 and headquartered in Deeside.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Pharmaceutical Development
Companies that use Quay Pharma
Customer profileIdeal customer profiles1 record
Quay Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Quay Pharma competitors and assessment
Company assessmentDirect peers
- Almac Group: Northern Ireland-headquartered contract development and manufacturing organisation serving global pharma with development, manufacturing, and clinical services. Highly comparable to Quay Pharma in offering breadth, mid-to-large size, and UK/Ireland regional base.
- Aenova: German-headquartered pharmaceutical CDMO offering development, manufacturing, and packaging of solid, semi-solid, and liquid dosage forms. Comparable to Quay Pharma as a mid-sized European contract manufacturer with similar service breadth.
- Siegfried Holding: Swiss-based CDMO providing API and finished drug product manufacturing services. Comparable to Quay Pharma in its integrated small-molecule development and manufacturing model.
- Cambrex: Contract development and manufacturing organisation providing API and finished dosage form services. Comparable to Quay Pharma in offering small-molecule CDMO services to pharma clients.
- Recipharm: European CDMO offering development, manufacturing, and packaging services across small molecules and biologics. Comparable to Quay Pharma in service mix and mid-sized European footprint.
- Piramal Pharma Solutions: India-headquartered CDMO offering integrated development, manufacturing, and packaging services globally. Comparable to Quay Pharma across the full CDMO value chain with a similar integrated-service pitch.
- Eurofins CDMO: European CDMO services arm of Eurofins providing contract development and manufacturing for small molecules and biologics. Comparable to Quay Pharma in service breadth and European base.
- PCI Pharma Services: Global CDMO focused on pharmaceutical and biopharmaceutical packaging, serialization, and manufacturing services. Comparable to Quay Pharma particularly across the packaging, labeling, and clinical-to-commercial supply chain segments.
Emerging players
- Asymchem: China-based CDMO offering API development and manufacturing with growing finished-dose capabilities. Comparable to Quay Pharma in the API/intermediate CDMO niche though at larger scale and with a different geographic centre of gravity.
Broad incumbents
- Catalent: One of the largest global CDMOs spanning development, manufacturing, and packaging across small molecules and biologics. Overlaps with Quay Pharma on every service line but at materially greater scale and geographic reach.
Market position
Customer concentration
Quay Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quay Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Quay Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quay Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quay Pharma
What does Quay Pharma do?
Quay Pharma is a contract development, manufacturing and packaging organisation serving the pharmaceutical industry. It delivers outsourced services across drug development, manufacturing, and packaging to pharmaceutical clients worldwide. The company operates as a private for-profit CDMO with 101–250 employees, founded in 2002 and headquartered in Deeside.
When was Quay Pharma founded?
Quay Pharma was founded in 2002. It employs 101 to 250 people.
Where is Quay Pharma based?
Quay Pharma is headquartered in Deeside, Australia, in the Oceania region.
Who are Quay Pharma's main competitors?
Direct peers on record are Almac Group, Aenova, Siegfried Holding, Cambrex, Recipharm, Piramal Pharma Solutions, Eurofins CDMO and PCI Pharma Services. Asymchem is listed as an emerging player. Catalent is listed as a broad incumbent.
Does Quay Pharma have an API?
No public API is recorded for Quay Pharma.
What industry is Quay Pharma in?
Quay Pharma's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.